Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), often complicates the course of cancer disease and represents an invariably distressing experience for cancer patients because of a substantial negative impact on their quality of life, morbidity and mortality [1].
